DNA09-A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of IMVT-1402 in Patients With Mild to Severe Generalized Myasthenia Gravis
Clinical Trial Grant
Awarded By
Immunovant
Start Date
June 30, 2025
End Date
April 7, 2034
Awarded By
Immunovant
Start Date
June 30, 2025
End Date
April 7, 2034